Literature DB >> 10467361

Inflammatory responses and their impact on beta-galactosidase transgene expression following adenovirus vector delivery to the primate caudate nucleus.

M S Lawrence1, H G Foellmer, J D Elsworth, J H Kim, C Leranth, D A Kozlowski, A L Bothwell, B L Davidson, M C Bohn, D E Redmond.   

Abstract

An E1, E3 deleted adenovirus vector, serotype 5, carrying the marker gene LacZ was bilaterally microinfused into the caudate nuclei of 10 St Kitts green monkeys. The location and number of cells expressing transgene and host immunologic response were evaluated at 1 week (n = 2) and 1 month (n = 8) following vector infusion. A large number of cells expressed beta-galactosidase in some monkeys, exceeding 600000 in one monkey, but no expression was seen in three of 10. All monkeys had positive adenoviral antibody titers before vector infusion, indicating the possibility of previous exposure to some adenovirus, but only one showed a significant increase in titer afterwards. Inflammatory cell markers revealed an inverse correlation between transgene expression and the extent of inflammatory response. Dexamethasone administered immediately before and for 8 days following vector delivery, however, had no effect on transgene expression. The demonstration of significant inflammatory responses in the brain of some individual primates, including demyelination, indicates the need for new generations of adenovirus vectors, or the successful suppression of inflammatory responses, before this vector is suitable for non-cytotoxic clinical applications in the CNS.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10467361     DOI: 10.1038/sj.gt.3300958

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  10 in total

Review 1.  The future of gene therapy for stroke.

Authors:  C A Gunnett; D D Heistad
Journal:  Curr Hypertens Rep       Date:  2001-02       Impact factor: 5.369

Review 2.  Nonneurotropic adenovirus: a vector for gene transfer to the brain and gene therapy of neurological disorders.

Authors:  Pedro R Lowenstein; Donata Suwelack; Jinwei Hu; Xianpeng Yuan; Maximiliano Jimenez-Dalmaroni; Shyam Goverdhana; Maria G Castro
Journal:  Int Rev Neurobiol       Date:  2003       Impact factor: 3.230

3.  In vivo transgene expression from an adenoviral vector is altered following a 6-OHDA lesion of the dopamine system.

Authors:  E M Torres; C Monville; P R Lowenstein; M G Castro; S B Dunnett
Journal:  Brain Res Mol Brain Res       Date:  2005-04-18

Review 4.  The potential application of gene therapy in the treatment of traumatic brain injury.

Authors:  Fang Shen; Liang Wen; Xiaofeng Yang; Weiguo Liu
Journal:  Neurosurg Rev       Date:  2007-08-09       Impact factor: 3.042

5.  Brain-specific expression of an exogenous gene after i.v. administration.

Authors:  N Shi; Y Zhang; C Zhu; R J Boado; W M Pardridge
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-09       Impact factor: 11.205

Review 6.  A Historical Review of Brain Drug Delivery.

Authors:  William M Pardridge
Journal:  Pharmaceutics       Date:  2022-06-16       Impact factor: 6.525

Review 7.  Blood-brain barrier transport of non-viral gene and RNAi therapeutics.

Authors:  Ruben J Boado
Journal:  Pharm Res       Date:  2007-06-08       Impact factor: 4.200

8.  The Trojan Horse Liposome Technology for Nonviral Gene Transfer across the Blood-Brain Barrier.

Authors:  Ruben J Boado; William M Pardridge
Journal:  J Drug Deliv       Date:  2011-11-16

9.  Systematic Comparisons of Formulations of Linear Oligolysine Peptides with siRNA and Plasmid DNA.

Authors:  Albert Kwok; David McCarthy; Stephen L Hart; Aristides D Tagalakis
Journal:  Chem Biol Drug Des       Date:  2016-02-01       Impact factor: 2.817

10.  Development of a nonhuman primate challenge model to evaluate CD8+ T cell responses to an adenovirus-based vaccine expressing SIV proteins upon repeat-dose treatment with checkpoint inhibitors.

Authors:  Richard Graveline; Morad Haida; Carolyne Dumont; Dominic Poulin; Florence Poitout-Belissent; Rana Samadfam; Sven Kronenberg; Franziska Regenass-Lechner; Rodney Prell; Marie-Soleil Piche
Journal:  MAbs       Date:  2022 Jan-Dec       Impact factor: 5.857

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.